See more : Leonteq AG (0QNE.L) Income Statement Analysis – Financial Results
Complete financial analysis of BioHarvest Sciences Inc. (CNVCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioHarvest Sciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Aurora Solar Technologies Inc. (ACU.V) Income Statement Analysis – Financial Results
- PT Ratu Prabu Energi Tbk (ARTI.JK) Income Statement Analysis – Financial Results
- The RealReal, Inc. (REAL) Income Statement Analysis – Financial Results
- Shree Rama Multi-Tech Limited (SHREERAMA.BO) Income Statement Analysis – Financial Results
- Sinoma Energy Conservation Ltd. (603126.SS) Income Statement Analysis – Financial Results
BioHarvest Sciences Inc. (CNVCF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.bioharvest.com
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc., together with its subsidiaries, offers nutraceutical super fruits and cannabis verticals in Israel and internationally. Its plant cell growth technology produces the active secondary metabolites without the need to grow the plant itself. The company designs, develops, manufactures, and markets Vinia, a red grape powder nutraceutical product; and medical cannabis. BioHarvest Sciences Inc. is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.67M | 5.50M | 2.10M | 396.00K | 218.00K | 449.00K | 325.00K | 40.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 7.04M | 4.28M | 1.43M | 258.00K | 189.00K | 463.00K | 493.00K | 240.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.63M | 1.22M | 670.00K | 138.00K | 29.00K | -14.00K | -168.00K | -200.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 44.45% | 22.17% | 31.87% | 34.85% | 13.30% | -3.12% | -51.69% | -500.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.37M | 2.31M | 4.13M | 1.26M | 1.35M | 553.00K | 429.00K | 388.00K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.68M | 5.05M | 1.80M | 4.57M | 848.00K | 778.00K | 160.55K | 89.51K | 118.52K | 189.50K | 60.75K |
| Selling & Marketing | 6.40M | 4.30M | 2.96M | 467.00K | 145.00K | 484.00K | 422.00K | 3.28K | 8.41K | 9.31K | 9.51K |
| SG&A | 12.07M | 9.35M | 4.76M | 5.04M | 993.00K | 1.46M | 160.55K | 92.78K | 126.94K | 198.81K | 70.25K |
| Other Expenses | 156.00K | 171.00K | 273.00K | 0.00 | 0.00 | 0.00 | 249.91 | 483.67 | 525.74 | 273.62 | 0.00 |
| Operating Expenses | 15.60M | 11.83M | 9.16M | 6.30M | 2.34M | 5.47M | 160.80K | 93.27K | 127.46K | 199.08K | 70.25K |
| Cost & Expenses | 22.64M | 16.11M | 10.59M | 6.56M | 2.53M | 5.93M | 160.80K | 93.27K | 127.46K | 199.08K | 70.25K |
| Interest Income | 0.00 | 0.00 | 0.00 | 193.00K | 758.00K | 1.99M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 936.00K | 508.00K | 805.00K | 611.00K | 3.76M | 0.00 | 3.95K | 6.54K | 2.15K | 1.93K | 406.17 |
| Depreciation & Amortization | 840.00K | 712.00K | 389.00K | 288.00K | 324.00K | 70.00K | 84.00K | 102.00K | 525.74 | 273.62 | 0.00 |
| EBITDA | -9.76M | -9.99M | -8.63M | -5.77M | -1.98M | -1.95M | -1.65M | -2.08M | -126.94K | -198.81K | -70.25K |
| EBITDA Ratio | -77.04% | -181.63% | -387.68% | -1,435.61% | -563.30% | -435.19% | -49.12% | -231.96% | 0.00% | 0.00% | 0.00% |
| Operating Income | -9.97M | -10.61M | -8.49M | -6.17M | -2.31M | -2.02M | -159.88K | -93.27K | -127.46K | -199.08K | -70.25K |
| Operating Income Ratio | -78.65% | -193.02% | -403.95% | -1,557.07% | -1,059.63% | -450.78% | -49.19% | -233.17% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.60M | -624.00K | -1.34M | -418.00K | -3.00M | -2.66M | -108.00K | 2.09M | -2.15K | -1.93K | -406.17 |
| Income Before Tax | -12.56M | -11.24M | -9.83M | -6.58M | -5.31M | -7.47M | -163.83K | -99.80K | -129.61K | -201.01K | -70.66K |
| Income Before Tax Ratio | -99.15% | -204.37% | -467.51% | -1,662.63% | -2,435.78% | -1,664.14% | -50.41% | -249.51% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -861.00K | 805.00K | 611.00K | 3.76M | -799.00K | 3.95K | 6.54K | 2.15K | 1.93K | 0.00 |
| Net Income | -12.56M | -11.24M | -9.83M | -6.58M | -5.31M | -6.67M | -1.85M | -3.50M | -131.76K | -201.01K | -70.66K |
| Net Income Ratio | -99.15% | -204.37% | -467.51% | -1,662.63% | -2,435.78% | -1,486.19% | -568.00% | -8,747.50% | 0.00% | 0.00% | 0.00% |
| EPS | -0.93 | -0.86 | -0.79 | -0.68 | -1.80 | -16.80 | 0.00 | 0.00 | -0.01 | -0.02 | -0.04 |
| EPS Diluted | -0.93 | -0.86 | -0.79 | -0.68 | -1.80 | -16.80 | 0.00 | 0.00 | -0.01 | -0.02 | -0.04 |
| Weighted Avg Shares Out | 13.53M | 13.05M | 12.45M | 9.71M | 2.95M | 397.20K | 0.00 | 0.00 | 13.76M | 12.16M | 2.00M |
| Weighted Avg Shares Out (Dil) | 13.53M | 13.05M | 12.45M | 9.71M | 2.95M | 397.20K | 0.00 | 0.00 | 13.76M | 12.16M | 2.00M |
BioHarvest Sciences Reports Q3 2023 Revenue Demonstrating Continued Growth Momentum
Q3 VINIA® revenues of USD 3.24M represent growth of 113% compared to Q3 2022 and 18% increase compared to Q2 2023 Year over Year Q3 Gross Profit improved from 18% to 45% Q4 2023 revenue range guidance of USD 4.2M...
BioHarvest Sciences raises C$11.78 million in first tranche of private placement
BioHarvest Sciences Inc said it has closed the first tranche of its previously-annouced C$13.5 million non-brokered private placement of convertible notes, raising C$11,786,489.90. The biotech company said the notes have a term of 24 months from date of issuance and bear...
BioHarvest Sciences Inc. Announces $11.78M Raised in First Tranche of $13.5M Private Placement
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 30, 2023) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) ("BioHarvest" or the "Company") is pleased to announce that it has closed the first tranche of its non-brokered private...
BioHarvest Sciences to raise up to $12M in convertible notes financing
BioHarvest Sciences Inc has announced its intention to raise proceeds of up to $12 million in a non-brokered private placement of convertible notes. The biotech company said the notes will have a term of 24 months from date of issuance and...
BioHarvest Sciences announces Health Canada license for VINIA sales in Canada
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) announced it has received a Canadian product license for VINIA from Health Canada's Natural and Non-Prescription Health Products Directorate. The company said the product license authorizes it to sell its flagship nutraceutical product derived from red grape...
Health Canada Grants BioHarvest Sciences License for VINIA Sales in Canada
Significant milestone marking the beginning of VINIA® geographical expansion beyond Israel and the US Further validation from global health authorities of BioHarvest's Botanical Synthesis Technology Platform Canadian Sales and Marketing to begin in early 2024 Vancouver, British Columbia and Rehovot,...
BioHarvest Sciences Inc. (CNVCF) Q2 Shareholder Presentation Call Transcript
BioHarvest Sciences Inc. (OTCQB:CNVCF) Q2 Shareholder Presentation Call September 6, 2023 2:30 PM ET Company Participants Justin Meiklem - Investor Relations Ilan Sobel - Chief Executive Officer Conference Call Participants Operator You have joined the meeting as an attendee and...
BioHarvest Sciences achieves 'significant milestone' with US sales of VINIA topping US$1M in August
BioHarvest Sciences Inc. (CSE:BHSC, OTC:CNVCF) has announced that monthly US sales of its flagship VINIA product surpassed $1 million in August 2023. The company said in a statement that the “significant milestone” marks a new inflection point in its journey...
BioHarvest Announces August 2023 U.S. VINIA Sales Exceeded USD $1Million
Significant milestone demonstrating sales momentum of VINIA® Further validation of the Botanical Synthesis Technology Platform Strong justification of the Direct-to-Consumer sales strategy Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - September 6, 2023) - BioHarvest Sciences Inc, (CSE: BHSC) (OTCQB:...
BioHarvest Sciences Reports Q2 2023 Results Demonstrating Continued Growth Momentum
Q2 VINIA® revenues of USD 2.75M represent growth of 228% compared to Q2 2022 and 27% compared to Q1 2023 Year over Year Q2 VINIA total active subscriber count grew by 620% Consumer average rating of 4.8/5 sets VINIA as...
Source: https://incomestatements.info
Category: Stock Reports